Johnson & Johnson To Start Coronavirus Vaccine Human Trials Ahead Of Schedule In July

Johnson & Johnson JNJ will begin the human clinical trials of its novel coronavirus (COVID-19) vaccine in July, the company announced Wednesday.

What Happened

The human trials of the Johnson & Johnson COVID-19 vaccine were earlier expected to begin in September.

The pharmaceutical company said 1045 volunteers, in the age groups of 18 to 55 and above 65, will participate in the phase 1/2 clinical trials, which will evaluate the safety, reactogenicity, and immunogenicity of the vaccine candidate.

"Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant," Johnson & Johnson Chief Scientific Officer Paul Stoffels said in a statement.

Why It Matters

The New Jersey-based company's vaccine is one of the five candidates considered by President Donald Trump's "Operation Warp Speed" as most likely to get regulatory approval, the New York Times reported.

Other lead vaccine candidate developers include Moderna Inc. MRNA, Pfizer Inc. PFE, AstraZeneca plc AZN, and Merck & Co. Inc. MRK.

What's Next

Johnson & Johnson said it in discussion with the National Institutes of Allergy and Infectious Diseases to start the third phase of its clinical trials ahead of schedule as well, if phase one results are favorable, and it gets necessary regulatory approval.

The company said it is also increasing its manufacturing capacity and talking with partners globally "to ensure worldwide access" once and if the vaccine is approved for preventative use against the coronavirus.

JNJ Price Action

Johnson and Johnson's shares closed nearly 1.3% higher at $147.80 on Wednesday. The shares were unchanged in the after-hours session.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsFDAMediaGeneralCovid-19Donald TrumpPharma StocksThe New York Timesvaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...